Showing results (241-250 of 261) with videos related to
Sort By:
Pageof 27
Dermatology and Therapy|January 13, 2022
Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 TrialDiamant Thaçi, Bruce Strober, Kenneth B Gordon, et al.Dermatology and Therapy|February 14, 2025
Lebrikizumab vs Other Systemic Monotherapies for Moderate-to-Severe Atopic Dermatitis: Network Meta-analysis of EfficacyJonathan I Silverberg, Thomas Bieber, Amy S Paller, et al.Multiple Sclerosis and Related Disorders|December 9, 2022
Network analysis characterizes key associations between subjective fatigue and specific depressive symptoms in early relapsing-remitting multiple sclerosisYuan-Ting Chang, Patrick K A Kearns, Alan Carson, et al.The Journal of Allergy and Clinical Immunology|November 10, 2024
Phase 2b randomized clinical trial of amlitelimab, an anti-OX40 ligand antibody, in patients with moderate-to-severe atopic dermatitisStephan Weidinger, Andrew Blauvelt, Kim A Papp, et al.The Journal of Investigative Dermatology|April 19, 2026
The role of biosimilars in enhancing global access to psoriasis treatmentYasmina Behlock, Sean P Gavan, Thomas Graier, et al.Brain Communications|October 10, 2024
Fatigue in early multiple sclerosis: MRI metrics of neuroinflammation, relapse and neurodegenerationRozanna Meijboom, Peter Foley, Niall J J MacDougall, et al.Proceedings. Biological Sciences|August 30, 2023
COVID-19 vaccine coverage targets to inform reopening plans in a low incidence settingEamon Conway, Camelia R Walker, Christopher Baker, et al.Journal of the Society for Cardiovascular Angiography & Interventions|January 14, 2025
Can Contrast Injections Cause or Propagate Coronary Injuries? Insights From Vessel and Guiding Catheter HemodynamicsDaniel Chamié, Rahul Bahl, Julio Maia, et al.Journal of Medicinal Chemistry|February 16, 2007
Flipped out: structure-guided design of selective pyrazolylpyrrole ERK inhibitorsAlex M Aronov, Christopher Baker, Guy W Bemis, et al.Medrxiv : the Preprint Server for Health Sciences|July 1, 2024
A causal link between autoantibodies and neurological symptoms in long COVIDKeyla Santos Guedes de Sa, Julio Silva, Rafael Bayarri-Olmos, et al.Pageof 27